Forty-two patients aged 1 to 18 months presenting to the emergency department
with wheezing. Patients excluded if history of cardiac/respiratory/musculoskeletal
disease, bronchodilation past 24 hrs, or history of 02 supplementation.
and Setting: Double-blind, prospective, placebo-controlled,
clinical crossover trail. Group 1 (n=19) received albuterol treatments
x2 followed by placebo treatment (oleic acid) q 20 minutes x2.
Group 2 (n=23) received placebo treatment q 20 minutes x2 followed by
albuterol treatments q 20 minutes x2.
Strict scoring system used for assessments at start, before each treatment,
and at the end of the study (study lasting 80 minutes). Scoring
for wheezing and retractions.
Group 1 scores (albuterol-placebo group) showed significant improvement
from baseline regarding wheezing after 2nd albuterol treatment (p<.01).
No statistical significant improvement with placebo treatments.
Group 2 scores (placebo-albuterol group) showed significant improvement
from baseline regarding wheezing, but only after 4th "treatment"
(p<.01) No statistical significant improvement with placebo treatments.
Group 1 scores, while improved with time, showed no statistical significant
improvement regarding retractions following either albuterol or placebo.
Group 2 scores showed a statistical improvement following the 4th "treatment"
(p<.05). No statistical improvement with placebo treatments.